Lilly reports positive hepatocellular carcinoma data for Cyramza

Lilly has announced top-line results from a phase III clinical trial showing the benefits its cancer drug Cyramza can deliver for people with hepatocellular carcinoma, also known as liver cancer.

The REACH-2 study analysed the drug's performance as a single agent in the second-line treatment of people with hepatocellular carcinoma, with Cyramza delivering significant overall and progression-free survival benefits.

REACH-2 is the first positive phase III hepatocellular carcinoma trial in a biomarker-selected patient population, enrolling patients unable to benefit from sorafenib treatment and with a high alpha-fetoprotein level.

Previously completed phase III studies of Cyramza have demonstrated significant benefits in treating advanced forms of gastric, non-small cell lung and colorectal cancer – three of the world's leading causes of cancer-related death.

Dr Levi Garraway, senior vice-president of global development and medical affairs at Lilly Oncology, said: "Lilly is encouraged by the results of REACH-2 and the potential for Cyramza to benefit patients in this setting."

Lilly intends to initiate new regulatory submissions for the drug in mid-2018.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.